Precision Biosciences Inc (DTIL) Stock Price, Quote & News

Company Profile

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with t...

Industry: Biotechnology

Sector: Healthcare

Phone: 919 314 5512

Fax: 480 393 5553

Website: precisionbiosciences.com

Address:

302 East Pettigrew St., Suite A-100, Durham, United States

schultzeee Mar. 10 at 10:22 PM

$DTIL will this be a $200 stock at the end of 2028? Or a $500 stock?

0 · Reply

revuelto Mar. 10 at 9:02 PM

$DTIL 🥳

0 · Reply

BillionerOfKing Mar. 10 at 5:34 PM

$DTIL Current Stock Price: $5.28 Contracts to trade: $5.0 DTIL Mar 20 2026 Call Entry: $0.27 Exit: $0.39 ROI: 45% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Impatient_Investor Mar. 10 at 4:03 PM

$DTIL will be back to below $4 after results. This garbage will not allow retailers to make money.

0 · Reply

Scrood_the_Pooch Mar. 10 at 3:14 PM

$DTIL So sorry you must declare BK, Puka.

0 · Reply

BobbyBalentino Mar. 10 at 3:05 PM

$DTIL anyone else's $5 calls not moving whatsoever?

0 · Reply

Scrood_the_Pooch Mar. 10 at 2:34 PM

$DTIL Our azer-cel- https://ca.finance.yahoo.com/news/imugene-reports-strong-early-response-002800853.html

0 · Reply

Love_To_Learn Mar. 10 at 2:07 PM

$XFOR $DTIL RAISING U UP

0 · Reply

StockNews_Live Mar. 10 at 11:03 AM

$DTIL 🎯 STOCK NEWS ALERT 💵 Price: $4.71 (+2.17%) 🔥 Sentiment Score: 95/100 🚀 VERY POSITIVE NEWS 📄 Precision BioSciences announced presentation of new preclinical study data supporting the potential long-term efficacy of PBGENE-DMD. The data presentation took place during a poster session at the… 📎 https://stocknews.live/news/DTIL/precision-bio-sciences-presents-21438.html

0 · Reply

OwenMcD Mar. 10 at 9:47 AM

$DTIL gene editing asymmetry, if biotech flow improves this could reprice quickly

0 · Reply

Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026

Mar 9, 2026, 4:15 PM EDT - 1 day ago

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026

Mar 9, 2026, 7:01 AM EDT - 1 day ago

Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event

Mar 2, 2026, 7:01 AM EST - 8 days ago

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

TGTX

Feb 18, 2026, 7:01 AM EST - 20 days ago

Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Feb 11, 2026, 7:01 AM EST - 27 days ago

Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy

Jan 12, 2026, 7:01 AM EST - 2 months ago

Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy

Dec 29, 2025, 3:40 AM EST - 2 months ago

Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026

Dec 23, 2025, 7:00 AM EST - 2 months ago

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Dec 4, 2025, 6:38 AM EST - 3 months ago

Precision Biosciences: Still Swinging And Finally Drawing Blood

Nov 19, 2025, 7:01 AM EST - 3 months ago

Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025

Nov 11, 2025, 4:11 PM EST - 4 months ago

Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B Transcript

Nov 10, 2025, 6:12 PM EST - 4 months ago

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants

Nov 10, 2025, 5:21 PM EST - 4 months ago

Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts

Nov 3, 2025, 7:01 AM EST - 4 months ago

Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 31, 2025, 7:01 AM EDT - 4 months ago

Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025

Oct 14, 2025, 7:01 AM EDT - 5 months ago

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025

Oct 9, 2025, 7:01 AM EDT - 5 months ago

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases

Oct 7, 2025, 7:01 AM EDT - 5 months ago

Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial

Sep 30, 2025, 7:01 AM EDT - 5 months ago

Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society

Sep 16, 2025, 5:52 AM EDT - 6 months ago

Precision BioSciences, Inc. (DTIL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 12, 2025, 7:01 AM EDT - 6 months ago

Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium

Sep 8, 2025, 7:01 AM EDT - 6 months ago

Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status

Aug 7, 2025, 7:01 AM EDT - 7 months ago

Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 7:01 AM EDT - 7 months ago

Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B

Aug 4, 2025, 7:01 AM EDT - 7 months ago

Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025

Jul 23, 2025, 7:01 AM EDT - 8 months ago

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Jul 16, 2025, 7:01 AM EDT - 8 months ago

Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic

Jun 25, 2025, 7:01 AM EDT - 9 months ago

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

May 15, 2025, 7:01 AM EDT - 10 months ago

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 4:30 PM EDT - 10 months ago

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 8, 2025, 7:01 AM EDT - 10 months ago

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

May 7, 2025, 7:01 AM EDT - 10 months ago

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

May 1, 2025, 7:01 AM EDT - 11 months ago

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Apr 15, 2025, 7:01 AM EDT - 11 months ago

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Apr 1, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

Mar 21, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Mar 20, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Mar 19, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 17, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

Mar 12, 2025, 8:00 AM EDT - 1 year ago

iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting

Feb 24, 2025, 7:01 AM EST - 1 year ago

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 19, 2025, 2:27 PM EST - 1 year ago

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Feb 19, 2025, 7:01 AM EST - 1 year ago

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Jan 29, 2025, 7:01 AM EST - 1 year ago

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

Jan 10, 2025, 2:18 PM EST - 1 year ago

Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst

Jan 9, 2025, 10:01 AM EST - 1 year ago

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Jan 9, 2025, 8:00 AM EST - 1 year ago

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Dec 18, 2024, 7:01 AM EST - 1 year ago

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

schultzeee Mar. 10 at 10:22 PM

$DTIL will this be a $200 stock at the end of 2028? Or a $500 stock?

0 · Reply

revuelto Mar. 10 at 9:02 PM

$DTIL 🥳

0 · Reply

BillionerOfKing Mar. 10 at 5:34 PM

0 · Reply

Impatient_Investor Mar. 10 at 4:03 PM

$DTIL will be back to below $4 after results. This garbage will not allow retailers to make money.

0 · Reply

Scrood_the_Pooch Mar. 10 at 3:14 PM

$DTIL So sorry you must declare BK, Puka.

0 · Reply

BobbyBalentino Mar. 10 at 3:05 PM

$DTIL anyone else's $5 calls not moving whatsoever?

0 · Reply

Scrood_the_Pooch Mar. 10 at 2:34 PM

$DTIL Our azer-cel- https://ca.finance.yahoo.com/news/imugene-reports-strong-early-response-002800853.html

0 · Reply

Love_To_Learn Mar. 10 at 2:07 PM

$XFOR $DTIL RAISING U UP

0 · Reply

StockNews_Live Mar. 10 at 11:03 AM

0 · Reply

OwenMcD Mar. 10 at 9:47 AM

$DTIL gene editing asymmetry, if biotech flow improves this could reprice quickly

0 · Reply

Impatient_Investor Mar. 10 at 5:49 AM

$DTIL Bankruptcy is the only option in the long run. This stock is definitely not investible. One more round of offering by end of this year will take the stock price to $1.0 or below.

0 · Reply

Impatient_Investor Mar. 10 at 5:44 AM

$DTIL Expecting another reverse split once it goes below 1 by this time next year.

0 · Reply

Retail_Contrarian Mar. 10 at 4:49 AM

$DTIL Are they reporting tomorrow or 3/24? The Overall sentiment climbing, Weekly MACD crossed up. Buy when others are fearful said a wise man. But what do I know I just talk to computers! 🤣🍻

0 · Reply

Lfrillman Mar. 10 at 2:12 AM

$BINI $DTIL $GPUS $IBRX nobody wants to hear your right wing extremist views here. Block.

0 · Reply

Rich_Man_Problems Mar. 10 at 12:35 AM

$GPUS $BINI $IBRX $DTIL This is just one example of the type of TRASH humans that some of you follow blindly, each day! People who have been indoctrinated (by sore losing far-left liberals with no political legs left to stand on) to hate America, Israel, and other allied nations are some of the WORST of humanity. "Her" account is now up for being permanently disabled on this platform...bye bye! Support the United States and its service members or move away to a country that will accept you, legally. Freedom is NOT free and should never be taken for granted. Whether Maui or Connecticut - the garbage always rises to the top! ✌️ No aloha, no tolerance.

2 · Reply

YoloAlfred Mar. 9 at 10:30 PM

$DTIL I will stop responding to him so all of you that have blocked him dont have to see his posts anymore .

1 · Reply

YoloAlfred Mar. 9 at 10:27 PM

$DTIL total fake price 18 shares has this @ $4.45

0 · Reply

YoloAlfred Mar. 9 at 10:15 PM

$DTIL First off...real question...how can i get paid to pump? Outside of buying a stock then pumping. Im dead serious..i will sign up tonight and i can start tomorrow morning @ 3am sharp

1 · Reply

Impatient_Investor Mar. 9 at 8:50 PM

$DTIL Insiders are selling a lot

1 · Reply

Scrood_the_Pooch Mar. 9 at 8:43 PM

$DTIL Recommendation: Ignore or block our whiny little f*ck.

0 · Reply

Impatient_Investor Mar. 9 at 8:13 PM

$DTIL the CEO of such a small biotech is making money as that of a big biotech company. I don't think he has ever done a significant buy and that tells the confidence he has in this scam company.

0 · Reply

Impatient_Investor Mar. 9 at 8:10 PM

$DTIL @YoloAlfred @Scrood_the_Pooch hey paid pumpers, when every other gene editing companies are up by more than 10%, this garbage was only 2%. All their previous partnerships were terminated including the latest one from Novartis after 3 years of their collaboration. Do I still need to have a hope on this garbage company?. The recent cheating was when it was raised to above 8 to just announce offering and fell down to 3.5 levels. This must be the worst gene editing company stock currently in the market.

1 · Reply

Market Cap	107.85M
Revenue (ttm)	68.70M
Net Income (ttm)	7.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	10.44%
Debt to Equity Ratio	1.35

Volume	480,100
Avg Vol	228,778
Day's Range	N/A - N/A
Shares Out	22.90M
Stochastic %K	93%
Beta	1.28
Analysts	Strong Sell
Price Target	$32.50